Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.

Similar Items

• Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.
  by: Shiori Hasegawa, et al.
  Published: (2017-01-01)
• Time-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug Events.
  by: Sayaka Sasaoka, et al.
  Published: (2016-01-01)
• Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004−2016
  by: Yumi Motooka, et al.
  Published: (2018-05-01)
• Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System
  by: Misa Naganuma, et al.
  Published: (2019-03-01)
• Analysis of fall-related adverse events among older adults using the Japanese Adverse Drug Event Report (JADER) database
  by: Haruna Hatahira, et al.
  Published: (2018-12-01)